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The most frequent neurodegenerative diseases (NDs) are Alzheimer’s disease (AD),
Parkinson’s disease (PD), and frontotemporal lobar degeneration associated with protein
TDP-43 (FTLD–TDP). Neuropathologically, NDs are characterized by abnormal intracellular
and extra-cellular protein deposits and by disease-speciﬁc neuronal death. Practically all
terminal stages of NDs are clinically associated with dementia. Therefore, major attention
was directed to protein deposits and neuron loss in supratentorial (telencephalic) brain
regions in the course of NDs.This was also true for PD, although the pathological hallmark
of PD is degeneration of pigmented neurons of the brainstem’s substantia nigra (SN).
However, PD pathophysiology was explained by dopamine depletion in the telencephalic
basal ganglia due to insufﬁciency and degeneration of the projection neurons located in
SN. In a similar line of argumentation AD- and FTLD-related clinical deﬁcits were exclu-
sively explained by supratentorial allo- and neo-cortical laminar neuronal necrosis. Recent
comprehensive studies in AD and PD early stages found considerable and unexpected
involvement of brainstem nuclei, which could have the potential to profoundly change our
present concepts on origin, spread, and early clinical diagnosis of these diseases. In con-
trast with PD and AD, few studies addressed brainstem involvement in the course of the
different types of FTLD–TDP. Some of the results, including ours, disclosed a higher and
more widespread pathology than anticipated. The present review will focus mainly on the
impact of brainstem changes during the course of the most frequent NDs including PD,
AD, and FTLD–TDP, with special emphasis on the need for more comprehensive research
on FTLDs.
Keywords: brainstem, human, pathology, neurodegenerative diseases, dementia, Alzheimer’s disease,
frontotemporal lobar degeneration, Parkinson’s disease
INTRODUCTION
Increased longevity in industrial and post-industrial countries is
inevitably associated with an increased prevalence of neurode-
generative diseases (NDs). Clinically, NDs implicate devastating
conditions causing enormous suffering of the affected individu-
als, and they impose a heavy burden on the families and society.
Therefore, considerable efforts are underway to improve diagno-
sis and to gain insight into the etiology and pathogenesis of these
diseases.
Neurodegenerative diseases share common characteristics:
(1) non-random anatomical progression associated with neuron
loss, (2) disease-speciﬁc intra- and extra-cellular protein deposits.
The most frequent NDs are: Alzheimer’s disease (AD), Parkinson’s
disease (PD), and frontotemporal lobar degeneration (FTLD). AD
is characterized by intracellular tau and extra-cellular amyloid-β
proteins, PD by intracellular positive α-synuclein deposits, and
FTLD by deposits of different proteins. Over 50% of the FTLD
cases are characterized byTARDNA-binding protein-43 (TDP-43)
positive inclusion.
The relationship between these deposits and neuronal loss is
a matter of dispute. However, most neuropathologists agree that
deposits are, at least, surrogatemarkers for speciﬁcNDs, sincemild
to moderate neuronal loss is difﬁcult to assess in routine parafﬁn
sections.
Progress in immunohistochemical methods, standardization
of the protocols, as well as using thick histological sections are
mandatory for establishing staging systems that describe the pro-
gression of the disease and correlate staging with clinical manifes-
tations. The ﬁnal goal behind these efforts is to uncover the initial
stages in individual NDs in order to develop therapies in the ear-
lier stages of the diseases and to validate therapeutic interventions
during disease progression.
Several staging systems have already been developed and are in
use for AD and PD (Braak and Braak, 1991; Mirra et al., 1991;
National Institute on Aging–Reagan Institute Working Group,
1997; Braak et al., 2003). There is no universally accepted stag-
ing system for FTLDs yet, since this group of diseases has been
described only recently. Recent results indicate that the currently
used staging systems donot cover all aspects of central nervous sys-
tem (CNS) pathology. This is especially true for the involvement
of the brainstem in the course of AD and FTLD–TDP.
This review will focus on the characteristic, non-random
anatomical sequence of lesions in the early stages of AD, PD, and
FTLD with special emphasis on the brainstem. In addition, we
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will point out gaps in our knowledge on brainstem involvement
in these conditions.
THE HUMAN BRAINSTEM
The brainstem is the central axis of the brain, and is considered an
intermediate regulatory system that links the spinal cord with the
superordinate prosencephalon. It represents an integration cen-
ter of responses directly aimed at the survival of the individual
by means of its somato-, branchio-, and visceromotor nuclei. The
brainstem is divided rostrocaudally intomidbrain,metencephalon
(pons and cerebellum), and medulla oblongata (Figure 1). The
brainstem is furthermore subdivided from dorsal to ventral into a
roof, a tegmentum, and a neencephalic basal part. The roof con-
sists of the midbrain quadrigeminal lamina and the metencephalic
cerebellum. The tegmentum represents the most conservative part
of the brainstem, comprising the sensory and motor nuclei of the
cranial nerves III through XII and the reticular formation. The
pyramidal tract, pontine nuclei, and the inferior olives compose
FIGURE 1 | Human brainstem. Sagittal view. The brainstem is divided
rostrocaudally into midbrain (orange), metencephalon (green), and medulla
oblongata (blue).
the neencephalic parts of the brainstem, which have considerably
enlarged relatively and absolutely in primates. Neencephalic com-
ponents have attained their greatest expansion in humans. The
reticular formation of the brainstem is an extended ill-deﬁned
network of interconnected neurons comprising the complete spec-
trum of neurons, from small- to giant-sized. In terms of compar-
ative anatomy, it is an old center of coordination that integrates
motor and sensory nuclei with cortical and spinal cord afferents.
Some of the reticular formation nuclei are believed to be involved
in primary homeostatic mechanisms, including gastrointestinal
regulation, pain perception, mood control, and sleep–wake cycles.
Consequently, the reticular formation is included into the greater
limbic system (Nieuwenhuys et al., 2008). In addition, speciﬁc
reticular formation nuclei produce aminergic transmitters such as
serotonin in the raphe nuclei, norepinephrine in the locus ceruleus
(LC), and dopamine in the substantia nigra (SN). The aminer-
gic nuclei project diffusely into the brain. Of particular interest,
aminergic nuclei are believed to transmit information via“volume
transmission.”Volume transmission suggests that the terminals of
the respective neuronal axons do not have a classical synaptic con-
formation. Therefore, the neurotransmitter is released into the
intercellular space and can affect a higher number of receptors
(Mountcastle, 1998). This kind of modulation is likely to impact
several different areas of the brain at once. No less important,
cholinergic cell groups are also found in the brainstem (Mesulam
et al., 1983). Thus, the brainstem represents an intersection where
mind and body could interact, making it paramount to place it
within an etiopathogenic context.
Most of the brainstem nuclei are long and narrow. Therefore,
the use of conventional horizontally cut histological slides may
cause the false impression that these nuclei are inconspicuous.
However, a closer look at 3D reconstructions invariably eliminates
this biased impression (Grinberg et al., 2010; Figure 2).
BRAINSTEM IN EARLY STAGES OF PARKINSON’S DISEASE
Parkinson’s disease is the secondmost commonneurodegenerative
disorder after AD, with an estimated prevalence of 1% in people
over 60 years of age. PD has been considered one of the best exam-
ples of pure movement-disorder for almost 150 years. Its hallmark
FIGURE 2 | Most of the brainstem nuclei are narrow in a dorsoventral
aspect, however, they extend for a considerable distance in a
rostrocaudal direction. Routinely used histological sections are cut in a
horizontal plan and just display the dorsoventral proﬁle of these nuclei causing
the impression that the these nuclei are inconspicuous. However, 3D
reconstructions of the nuclei demonstrate their real signiﬁcant volume. (A)
Horizontally cut section at the level of the rostral pons. The black structure is a
reconstruction of the locus ceruleus. Note the small proﬁle at the intersection
between the reconstruction and the horizontally cut histological slide. (B)
Horizontally cut section at the level of the medulla oblongata. The blue
structure is a reconstruction of the raphe magnus nucleus. As in the previous
example, this structure looks inconspicuous in a horizontally cut section.
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is the degeneration of the pigmented neurons of the midbrain part
of the brainstem. The pigmented neurons of the SN are supplying
the basal ganglia with dopamine. From 30 to 70% of neuronal
loss is considered to cause clinical relevant dopamine depletion in
basal ganglia circuits (Cheng et al., 2010). Therefore, although the
SN belongs to the brainstem, the disease manifestation was mainly
associated to supratentorial disturbances.
Many non-motor symptoms were described in PD patients,
but they were mostly regarded as unassociated to PD lesions in the
brain. This scenario changed dramatically from 2003, when Braak
et al. (2003) put ﬁndings in context by conﬂating and extending
various previous studies in PD. They provided a chronological
scheme for the spread of Lewy bodies during the disease course,
and demonstrated that several brainstem nuclei are involved by
PD-type changes evenbefore the SN(Braak et al., 2003). Thedorsal
motor nucleus of the vagus (DNX), located in the caudal medulla
oblongata, and the olfactory bulb, are the two areas thought to
be ﬁrst affected in the brain (Braak et al., 2003). In addition, all
serotoninergic nuclei, select cholinergic, noradrenergic, some pre-
cerebellar, and cranial nerve nuclei, and the reticular formation,
are vulnerable to PD. It is now accepted that the SN is affected only
in stage III, and the ﬁrst motor symptoms are usually detected in
stage IV, by which time most of the SN has already degenerated. In
addition, they showed that a number of non-vulnerable neurons
keep their integrity throughout the disease. It suggests that neu-
ronal damage is not arbitrary in PD (Braak et al., 2003), although
the reason for this selective vulnerability is still unclear.
After these ﬁndings, it was possible to correlate many of the
non-motor, non-speciﬁc symptoms – such as autonomic dysfunc-
tion, depression, and sleep disorders – to the biological changes
occurring in the brainstem (Grinberg et al., 2010). For instance, the
general visceroefferent DNX controls the postganglionic parasym-
pathetic nerve cells of the enteric and cardiac system. Symptoms
such as constipation, dysphagia, and drooling, which may precede
the motor PD features for years (Pfeiffer, 2003; Kaufmann et al.,
2004), are believed to be partly caused by DNX degeneration.
Another example was the conclusion that a speciﬁc and dev-
astating sleep disorder, the REM-sleep behavior disorder (RBD),
may arise as a direct manifestation of PD damage in the chief
brainstem nuclei (Ondo et al., 2001). Actually, RBD is likely to
be a better marker of a synucleinopathy than parkinsonism is.
RBD is characterized by the loss of normal skeletal muscle atonia
during REM-sleep, with prominent motor activity and dream-
ing enactment (Boeve et al., 2007). The cholinergic neurons of
the pedunculopontine nucleus, degenerated in PD stage III, are
directly involved in promoting REM-sleep. In addition, the LC
and the dorsal raphe (DR) nucleus, affected respectively in stages
II and III, also participate in the regulation of sleep (Saper et al.,
2001), whereas the caudal raphe participates in suppressing the
locomotor activity during sleep (Lai and Siegel, 1999). For addi-
tional information about the brainstem nuclei involved in early
PD stages and their clinical counterpart (see Grinberg et al.,
2010).
These ﬁndings have dramatically changed our view, and PDwas
redeﬁned in the last few years as a multisystem disorder involving
general visceromotor system, reticular formation, and isodendritic
brainstem core and thus, several neurotransmitter systems, and
it is characterized by motor and non-motor symptoms. Patients
now beneﬁt from improved management of formerly neglected
symptoms (Obeso et al., 2010).
However, the precise pathways linking the chronologically and
topographically early affected centers with later affected cortical
and subcortical structures need to be unraveled. What is the rela-
tionship between peripheral ganglia α-synucleinopathy and the
involvement of the DNX and intermediate reticular formation?
Is there a direct pathway involved in propagating α-synuclein
deposits between the olfactory bulb and the DNX, or do they
suffer independent involvement? In case there is a direct pathway,
is the spread antero- or retro-grade? Which pathways are related
to involvement of the isodendritic core (IC), including the SN, LC,
and DR nucleus?
BRAINSTEM IN EARLY STAGES OF ALZHEIMER’S DISEASE
Like PD, AD is a progressive and, so far, incurable dementia. It
accounts for 50 to 70% of all dementia cases. In the same fashion
as all NDs, AD is characterized neuropathologically by accumula-
tive lesions (protein deposits) and degenerative lesions (neuronal
loss). AD accumulative lesions constitute its two neuropathologi-
cal hallmarks: (1) accumulation of extra-cellular β-amyloid in the
form of neuritic plaques, and (2) intracellular accumulation of
phosphorylated-tau in the form of neuroﬁbrillary tangles (NFT),
neuropil threads, and dystrophic neurites. Cognitive decline in
AD correlates best with neuronal loss, followed by NFT spread,
whereas the neuritic plaque burden is only slightly associated with
cognitive decline (Berg et al., 1998; Giannakopoulos et al., 2003).
As with Lewy bodies in PD, NFT-pathology in AD follows a
characteristic, non-random anatomical progression. This stereo-
typical progression, demonstrated by detailed neuropathological
studies, is the base for the currently used Braak and Braak staging
system (Braak and Braak, 1991). According to this system, NFTs
progression can be staged in six grades. NFTs are conﬁned to the
transentorhinal region in stage I, and they will reach the primary
neocortical areas in stage VI. However, the Braak and Braak stag-
ing is conﬁned to allo- and neo-cortical ﬁelds, and thus does not
address brain changes in the brainstem. Probably, this may partly
explain whyAD has been featured as a basically supratentorial dis-
ease. Numerous studies conﬁrmed regular brainstem involvement
in AD, but this involvement was mostly regarded as secondary to
supratentorial changes (Hardy et al., 1986).
Finally in 2009,using a postmortembrain collection focused on
normal aging, it was demonstrated that the midbrain DR nucleus
shows NFTs before the Braak and Braak I’s transentorhinal region.
In this study of 118 cases, 100%of the 80 subjects inwhich transen-
torhinal region was affected by NFTs also showed NFTs in the DR.
In addition, 22% of the 38 subjects who had no cortical NFTs
(Braak 0) showed NFTs in the DR (Grinberg et al., 2009). Inter-
estingly, the NFT burden in the DR is proportional to the Braak
and Braak stage (Rub et al., 2000; Grinberg et al., 2009). This ﬁnd-
ing suggests that brainstem areas are affected by AD before the
supratentorial regions. The demonstration that the DR is likely to
be affected by AD in its earliest stages drew new attention to the
brainstem, and motivated new studies and revived old hypothe-
ses (Simic et al., 2009). In addition, because the DR produces a
great part of the brain serotonin, its degeneration may explain
www.frontiersin.org July 2011 | Volume 2 | Article 42 | 3
Grinberg et al. Brainstem in neurodegenerative diseases
the depressive symptoms experienced by many AD patients, years
before the cognitive changes’ onset (Panza et al., 2010).
However, the DN is not the sole brainstem nucleus involved
in AD early stages. The DN, together with the LC, the SN, and
the telencephalic cholinergic nucleus basalis of Meynert (NbM)
form the IC (Figure 3), an interconnected network, whose neu-
rons share morphological features, such as big somata, overlap-
ping dendritic ﬁelds, predominantly poorly myelinated axons that
extend to distant projection sites, and aminergic/cholinergic vol-
ume transmission. The IC is involved in modulation of many
basic physiologic processes (Ramon-Moliner and Nauta, 1966)
and it is intimately connected with those areas of the cerebral
cortex that undergo early neuroﬁbrillary changes in AD (Insausti
et al., 1987). Several studies reported the early existence of NFTs
and/or neuronal loss in the LC, the SN, and the cholinergic NbM
(Ohm et al., 1989; Sassin et al., 2000; Lyness et al., 2003; Geula
et al., 2008). However, very few previous studies addressed these
four nuclei as a network, which is necessary for effectively study-
ing possible interactions of all major pathogenic factors of this
process in the same brain (Simic et al., 2009). The great major-
ity of the studies focused either on neuronal loss or on protein
inclusion. Although heavily explored, the relationship between
neuronal loss and NFT- and NP-burden in AD is yet to be settled.
Recent evidence suggests that this relationship is not as simple
as it was originally considered (Arendt et al., 1985; Cras et al.,
1995; Kril et al., 2002). For instance, out of the IC nuclei, the
NbM and LC show the greatest neuronal loss, but not the great-
est inclusion burden (Lyness et al., 2003). Furthermore, there
are many disparities among studies on individual nuclei of the
IC, which may be attributed to the use of biased morphological
methods and the use of outdated pathological criteria (Khacha-
turian, 1985). This implies that many of erstwhile control cases
would be considered early state AD by current standards (see
Introduction).
Other limitations were the lack of age matched control groups,
and the use of cases with long postmortem interval, which causes
autolysis of the neuronal cells (Lyness et al., 2003). Regardless of
the difﬁculties, due to the evidence of early involvement of the
IC in AD, it is worthwhile to make an effort to clarify its role in
this disease. Further studies are sought to determine at which AD
stage the other components of the IC become affected, and how
the involvement of each of these nuclei reﬂects into the other. If
it can be proven that the IC is affected early in AD, strategies to
protect these neurons may delay the progression of the disease
to supratentorial regions. In addition, this knowledge may help
to improve clinicopathological correlations, especially concerning
non-speciﬁc symptoms seen in AD prodromal stages. Over 90%
of ADpatients experience behavioral and psychological symptoms
before onset of cognitive decline (Devanand et al., 1997), and some
of these symptoms may be related to IC degeneration. Even today,
the most used drugs for symptomatic treatment of AD, such as
acetylcholinesterase inhibitors, aim to compensate for symptoms
related to IC abnormalities.
Besides the IC, other brainstem structures were reported as
early involved in AD, such as the tegmentopontine reticular
nucleus (nucleus of Bechterew), which is part of the premotor
oculomotor circuit (Rub et al., 2001). However, further studies are
needed to determine how early and consistently these nuclei are
affected.
The widely used Braak and Braak staging system gives an
impressive example of how pathological intraneuronal tau ﬁb-
rils will accumulate ﬁrst in mesocortical, afterward in allocortical,
and ﬁnally in isocortical neurons in a unvaried and layer-speciﬁc
manner. Presently we do not know the mechanism that lies behind
FIGURE 3 | Isodendritic core.The components of this network share
morphological features, such as neurons with big somata, overlapping
dendritic ﬁelds, predominantly poorly myelinated axons that extend to distant
projection sites, and aminergic/cholinergic volume transmission. The
isodendritic core is involved in modulation of many basic physiologic
processes (Ramon-Moliner and Nauta, 1966). This ﬁgure shows the
representation of the Isodendritic core components: dorsal nucleus of the
raphe (red), locus ceruleus (dark blue), substantia nigra (pars compacta in
black and pars diffusa in light blue), and the telencephalic cholinergic nucleus
basalis of Meynert (green). (A) Medial view. (B) Dorsomedial view.
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this systemic spread of pathologic neuronal changes. However, it
is likely to use major pathways including the trisynaptic neuronal
circuit and cortical primary, unimodal, and polymodal associa-
tional layer 3 and layer 5 pyramidal cell interconnections. The
emergence of pathological tau ﬁbrils within neurons of these
interconnected circuits is reversed compared to the ﬂow of infor-
mation processing via primary sensory, unimodal, and polymodal
association cortices to limbic regions (Mesulam, 1998) and thus,
considered to progresses in a feedback manner. At ﬁrst sight,
early Alzheimer’s-related tau pathology in brainstem nuclei does
not ﬁt into this concept of telencephalic feedback propagating
pathology. However, both the DR nucleus and the LC are con-
nected to the prefrontal cortex, and thus are supplied with highly
processed polymodal information. By virtue of these afferents, the
brainstem nuclei could represent ﬁnal targets of information pro-
cessing. By means of their widespread afferent projections, they
are in a position to modulate disparate brain regions including
the telencephalon, diencephalon, and the brainstem in a way to
generate integrated somatomotor, visceromotor, and endocrine
responses. Consequently, the IC represents a major component
of limbic brainstem core and paracore zones, as proposed by
Nieuwenhuys (1996).
FRONTOTEMPORAL DEMENTIAS
Frontotemporal dementias (FTDs) comprise a major group of
incurable and incapacitating NDs. In the last few years, they have
been transformed from a secondary entity into a major focus
of dementia neuroscience research. They are estimated to affect
400,000 Americans younger than 65 years of age (Maslow, 2006),
making it as prevalent asAD in this age group. Furthermore, recent
evidence suggests that FTDs are frequent also in older populations
(Ratnavalli et al., 2002; Rosso et al., 2003).
The entities belonging to the FTD group have overlapping clin-
ical and pathologic features. They usually present with marked
declines in socioemotional functioning, and behavioral or lan-
guage disturbances (Kramer et al., 2003). The current FTD
research criteria deﬁne three clinical syndromes: (1) frontotem-
poral dementia or behavioral variant FTD, (2) semantic dementia
or temporal variant FTD, and (3) progressive non-ﬂuent aphasia
(Neary et al., 1998). Recently, the deﬁnition and diagnostic crite-
ria for the language variants (semantic dementia and progressive
non-ﬂuent aphasia) have been revised. Thenewcriteria recognized
three subtypes of primary progressive aphasia (PPA): non-ﬂuent
or agrammatic variant, semantic variant, and logopenic variant
(Gorno-Tempini et al., 2011). In addition, some cases may present
as progressive supranuclear palsy (PSP), or corticobasal syndrome,
and even concomitant motor neuron disease (Kertesz and Munoz,
2004; Liscic et al., 2008). Traditionally, damage to frontal and
temporal lobe cortical regions are accounted as the cause of the
majority of the clinical abnormalities characteristic of FTDs. Thus,
FTDs would predominantly represent telencephalic NDs.
The FTDs may be underlaid by different neuropathological
entities. Theoverarchingname for theseneuropathological entities
is FTLD. Therefore, FTLD will be used here as a neuropathological
term, while FTD is used as a clinical term. All these entities share
some neuropathological features, such as vacuolation, gliosis, and
neuronal loss of the superﬁcial cortical layers, especially in frontal
and temporal areas. However, as in the other NDs, classiﬁcation
of the heterogeneous group of FTLD disorders is based on the
protein composition of intracellular abnormal deposits (Cairns
et al., 2007). The most frequent form of FTLD is associated with
deposits composed of the TDP-43, and it is called FTLD–TDP.
Recent evidence suggests that FTLD–TDP can be further subdi-
vided into at least three histologic variants, based on the patterns
of TDP-43 immunoreactivity (Mackenzie et al., 2006; Sampathu
et al., 2006).
The second most common FTLD form is characterized by
phospho-tau deposits, both in neurons and glia. They are called
tauopathies, or more recently FTLD-tau (Mackenzie et al., 2010).
The FTD clinical picture is indicative of the affected brain
region, either orbitofrontal, dorsolateral prefrontal, temporal, and
so on. However, a brain region can be hit by different FTLD enti-
ties, and therefore it is not possible to determine the biochemical
signature of a FTD case based exclusively on the clinical and imag-
ing features. This review will focus only in FTLD–TDP, the most
prevalent form of FTLD.
BRAINSTEM IN EARLY STAGES OF FTLD–TDP
Macroscopically, FTLD–TDP is characterized by peculiar and
asymmetric widened sulci and ﬂattened gyri in the frontal and
temporal region. Therefore, FTLD–TDPs were initially considered
to be conﬁned to the telencephalic cortex. However,more compre-
hensive studies have also demonstrated some signiﬁcant brainstem
changes in the FTLD–TDP. These studies were either performed
prior to the modern biochemical characterization of FTLDs or
using a limited number of cases (Lüers and Spatz, 1957; Jakob,
1960, 1979; Yang and Schmitt, 2001). Degeneration of brainstem
nuclei was considered as a consequence of anterograde degenera-
tion due to death of subcortically projecting isocortical pyramidal
cells. In contrast to this prevailing conjecture, Poppe and Tennst-
edt (1964) suggested early brainstem involvement in describing a
patient presenting what would be classiﬁed as a behavioral variant
FTD. Their hypothesis challenged contemporary beliefs. However,
for historical and technical reasons it is not possible to reclassify
the Poppe and Tennstedt case into the presently used diagnostic
system.
So far, only a few recent studies addressed the neuropatholog-
ical alterations in the brainstem in context with TDP-43. These
studies focused mainly on motor-related nuclei. Not surprisingly,
most of the changes were found in cases with coincident motor
neuron disease (FTLD–MND; Dickson et al., 2007; Pikkarainen
et al., 2008; Davidson et al., 2009). Unexpectedly, Davidson et al.
(2009) explicitly stated that deposits were absent in the pontine
nuclei in all FTLD–TDP subtypes. Other non-motor nuclei were
practically neglected in the recent studies.
Regarding neuronal loss in brainstem of FTLD–TDP cases,
Yang and Schmitt (2001) compared the amount of neuronal loss
and ubiquitin deposits in selected brainstem nuclei of 12 FTLD
without tau-positive deposits, 30 AD and 35 controls. They found
signiﬁcant neuronal loss in the DR nucleus and nucleus centralis
superior of the pons, but none in the LC in FTLD cases. Deposits
were not found in any of the aminergic nuclei examined. Similarly
www.frontiersin.org July 2011 | Volume 2 | Article 42 | 5
Grinberg et al. Brainstem in neurodegenerative diseases
to PD and AD, the serotonergic system is apparently susceptible
to FTLD–TDP. At variance with PD and AD, the LC seems to be
spared in FTLD–TDP.
In order to ﬁll existing gaps concerning brainstem pathology
during the course of all FTLD–TDP subtypes, we conducted a
screening study using 14 cases belonging to the UCSF Neurode-
generative Disease Brain Bank. The cases comprised all clinical
and pathological spectra of FTLD–TDP (Table 1). Five TDP-43
immunostained horizontal sections at the level of the midbrain,
rostral pons, caudal pons, and medulla oblongata were screened
in each case. The microscopic assessment was done using a high
magniﬁcation objective, and covered the whole slide. This strategy
aimed to prevent topographical mapping during the screening.
The exact location of each inclusion found was recorded with
the aid of an optical marker attached to the microscope. All
deposits were photographed and categorized. At the end of each
screening, a map was generated and used to locate the deposits
in each section. Later on, clinical and pathological information
were added.
TAR DNA-binding protein-43 deposits were present in the
brainstems of all cases (Table 1). Size, shape, and intracellular
location of the deposits predicted the individual cortical subtype,
suggesting that every FTLD–TDP subtype has a ﬁngerprint also
in the brainstem. Strikingly, the superior colliculus (SC) showed
deposits in all the cases analyzed. The SC is a layered structure
located at the midbrain tectum and it is interconnected with
several cortical and subcortical structures. The SC plays several
roles in modulating eye movements (e.g., generating the orient-
ing response to visual or auditory stimuli) and is involved in the
initiation of saccades. It is also important for the suppression of
unwanted saccades when steady ﬁxation is necessary (Nieuwen-
huys et al., 2008). In fact, an imaging study by Cardenas et al.
(2007) demonstrated atrophy of the midbrain tectum, in which
the SC is located, in FTLD cases.
The SC is part of the premotor oculomotor network (Figure 4).
This network is mostly located in the brainstem tegmentum, gen-
erates and modulates several eye movements, and coordinates
the activity of the three oculomotor brainstem nuclei (Leigh
and Zee, 2006; Rub et al., 2009). In our screening study, the
components of the premotor oculomotor network were variably
involved. Neuropathologically, premotor ocular network abnor-
malities were found in all FTLD–TDP subtypes, but clinical studies
showed absence of oculomotor abnormalities in semantic demen-
tia patients (Boxer et al., 2006; Garbutt et al., 2008; Sturm et al.,
2011). Therefore, it was surprising to ﬁnd neuropathological
changes in the preocular motor nuclei of the semantic demen-
tia cases we analyzed. The meaning of these deposits should be
further elucidated.
Furthermore, the pontine nuclei, inferior olive, and the SNwere
affected in all subtypes. Changes to these nuclei are associated with
motor abnormalities.
In summary, the research on brainstem changes in FTLD–TDP
by means of state-of-the-art methods is still incipient and partly
controversial. Most investigators obviously consider the involve-
ment of brainstem nuclei in context with an anterograde degener-
ation and, therefore, as a logical consequence of primary cortical
neuron loss. Different subtypes of FTLD–TDP are associated with
FIGURE 4 | Premotor oculomotor nuclei. (A) Brain stem scheme of a
frontal section cut perpendicular to the intercommissural axis of Forel
showing the rostral midbrain. The Rostral interstitial nucleus of the medial
longitudinal fascicle is part of the premotor oculomotor system.These cells,
which are embedded in MLF showTDP-43 inclusions in FTLD–TDP cases.
(B) Brain stem scheme of a horizontal section through the caudal midbrain
with the superior colliculus (SC). TDP-43 inclusions were found in the SC in
all the cases examined. (C) Brain stem scheme of a horizontal section
through the mid-level of the pons with the reticulotegmental nucleus of the
pons (RTTG; nucleus Bechterew) and the medial longitudinal fascicle
(MLF ). (D) Brain stem scheme of a horizontal section through the caudal
pons with the raphe interpositus nucleus (RIP), and the MLF. Abbreviations:
A, aqueduct; CG, central gray; CM, centromedian nucleus of the thalamic
central complex; DRC, dorsal raphe nucleus, caudal part; EW,
Edinger-Westphal nucleus; GI, gigantocellular reticular nucleus; GRN, great
raphe nucleus; ICP, inferior cerebellar peduncle; LR, linear raphe nucleus;
MD, mediodorsal nucleus of the thalamus; MEV, mesencephalic trigeminal
tract; ML, medial lemniscus; MLF, medial longitudinal fascicle; MOV, motor
trigeminal nucleus; PAG, periaqueductal gray; PBB, pontobulbar body; PF,
parafascicular nucleus of the thalamic central complex; PL, paralemniscal
nucleus; PN, pontine nuclei; PNC, pontine reticular formation, caudal
nucleus; PNO, pontine reticular formation, oral nucleus; PV, paraventricular
nuclei of the thalamus; R, red nucleus; RIP, raphe interpositus nucleus; ri
MLF, rostral interstitial nucleus of the medial longitudinal fascicle; RTTG,
reticulotegmental nucleus of the pons (nucleus Bechterew); SC, superior
colliculus; SCP, superior cerebellar peduncle; SN, substantia nigra; SO,
superior olive; SCP, superior cerebellar peduncle; SPF, subparafascicular
nucleus of the thalamic central complex; SUV, superior vestibular nucleus;
III, oculomotor nucleus; III, oculomotor nerve; VI, abducens nucleus; VI,
abducens nerve; VII, facial nucleus; VII, facial nerve 3V, third ventricle; 4V,
fourth ventricle.
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Table 1 | Summary of cases screened for FTLD–TDP.
Case Clinical
phenotype
FTLD–TDP
subtype
Age at
onset (y )
Disease
duration (y )
SC RIC miRLF RTTG Pons IO RN SN
1 sPPA (right variant) 1 44 18 Yes No NA No Yes Yes No No
2 sPPA (right variant) 1 53 12 Yes NA No NA Yes No No No
3 sPPA (right variant) 1 62 14 Yes No NA No Yes Yes Yes Yes
4 sPPA (right variant) 1 64 12 Yes No No NA Yes Yes No No
5 sPPA (left variant) 1 62 12 NA No No No No No No Yes
6 FTD+MND 2 48 1 Yes Yes Yes Yes Yes Yes Yes Yes
7 FTD+MND 2 55 3 Yes Yes Yes Yes Yes Yes NA Yes
8 FTD+MND 2 56 3 Yes Yes NA Yes Yes Yes NA Yes
9 bvFTD+MND 2 62 4 Yes NA Yes NA Yes Yes Yes Yes
10 bvFTD 2 72 3 Yes No No No Yes Yes No Yes
11 nfPPA 3 63 10 Yes NA NA NA Yes Yes NA Yes
12 nfPPA 3 68 10 Yes Yes No No Yes No Yes Yes
13 nfPPA/CBS 3 69 5 Yes Yes Yes No Yes Yes Yes Yes
14 CBS 3 57 9 Yes NA NA Yes Yes Yes Yes Yes
%Type 1 100 0 0 0 60 60 20 40
%Type 2 100 75 75 60 100 100 66 100
%Type 3 100 50 50 25 100 75 75 100
Type according to Sampathu et al. (2006). Clinical phenotypes – bvFTD, behavioral variant frontotemporal dementia; CBS, corticobasal syndrome; FTD+MND, fron-
totemporal dementia with motor neuron disease; nfPPA, non-ﬂuent variant primary progressive aphasia; sPPA, semantic variant primary progressive aphasia. Premotor
oculomotor nuclei – SC, superior colliculus; RIC, raphe interpositus; RN, red nucleus; RTTG, reticulotegmental nucleus of the pons; miRLF, rostral interstitial nucleus
of the medial longitudinal fascicle; IO, inferior olive.
a highly characteristic pattern of brainstem neuropathology that
leaves a kind of ﬁngerprint which could help in understanding
the etiopathogenesis of these diseases. Furthermore, the SC is
invariably affected in all FTLD–TDP subtypes, indicating a spe-
cial vulnerability of the oculomotor system in the course of this
disease. Given the unexpected previous and recent ﬁndings in the
brainstems of AD and PD patients, it is plausible and it seems
rewarding to subject the brainstem of FTLD–TDP patients to a
more comprehensive investigation.
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